These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22826885)

  • 1. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers.
    Al-Hallak MH; Sarfraz MK; Azarmi S; Roa WH; Finlay WH; Löbenberg R
    Ther Deliv; 2011 Oct; 2(10):1313-24. PubMed ID: 22826885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary drug delivery by powder aerosols.
    Yang MY; Chan JG; Chan HK
    J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-use disposable dry powder inhalers for pulmonary drug delivery.
    Friebel C; Steckel H
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1359-72. PubMed ID: 21080859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nanoscale in pulmonary delivery. Part 2: formulation platforms.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
    Lin YW; Wong J; Qu L; Chan HK; Zhou QT
    Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhalable nanoparticulate powders for respiratory delivery.
    Muralidharan P; Malapit M; Mallory E; Hayes D; Mansour HM
    Nanomedicine; 2015 Jul; 11(5):1189-99. PubMed ID: 25659645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry Powder form of Polymeric Nanoparticles for Pulmonary Drug Delivery.
    Shiehzadeh F; Tafaghodi M
    Curr Pharm Des; 2016; 22(17):2549-60. PubMed ID: 26818872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel dry powder inhaler particle-dispersion systems.
    Donovan MJ; Gibbons A; Herpin MJ; Marek S; McGill SL; Smyth HD
    Ther Deliv; 2011 Oct; 2(10):1295-311. PubMed ID: 22826884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can we bring high drug doses to the lung?
    Claus S; Weiler C; Schiewe J; Friess W
    Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition.
    Liao Q; Yip L; Chow MYT; Chow SF; Chan HK; Kwok PCL; Lam JKW
    Int J Pharm; 2019 Apr; 560():144-154. PubMed ID: 30731259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of disposable inhalers in pulmonary drug delivery.
    de Boer AH; Hagedoorn P
    Expert Opin Drug Deliv; 2015 Jan; 12(1):143-57. PubMed ID: 25374325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review on Micro and Nanoengineering in Powder-Based Pulmonary Drug Delivery.
    Pasero L; Susa F; Limongi T; Pisano R
    Int J Pharm; 2024 Jun; 659():124248. PubMed ID: 38782150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Devices for dry powder drug delivery to the lung.
    Berkenfeld K; Lamprecht A; McConville JT
    AAPS PharmSciTech; 2015 Jun; 16(3):479-90. PubMed ID: 25964142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Inspiratory Pressures in Determining the Flow Rates Though Dry Powder Inhalers; A Review.
    Clark AR
    Curr Pharm Des; 2015; 21(27):3974-83. PubMed ID: 26290203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation and clinical perspectives of inhalation-based nanocarrier delivery: a new archetype in lung cancer treatment.
    Bardoliwala D; Javia A; Ghosh S; Misra A; Sawant K
    Ther Deliv; 2021 May; 12(5):397-418. PubMed ID: 33902294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the role of swirling flow in dry powder inhalers: Implications for design considerations and pulmonary delivery.
    Chen J; Ye Y; Yang Q; Fan Z; Shao Y; Wei X; Shi K; Dong J; Ma Y; Zhu J
    J Control Release; 2024 Sep; 373():410-425. PubMed ID: 39038545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalable Nanoparticle-based Dry Powder Formulations for Respiratory Diseases: Challenges and Strategies for Translational Research.
    Chan HW; Chow S; Zhang X; Zhao Y; Tong HHY; Chow SF
    AAPS PharmSciTech; 2023 Apr; 24(4):98. PubMed ID: 37016029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry powder inhalation: past, present and future.
    de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
    Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
    Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
    Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.